Last reviewed · How we verify
Vincentage Pharma Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| VCT220 Tablet | VCT220 Tablet | phase 3 | PCSK9 inhibitor | PCSK9 | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
- Amgen · 1 shared drug class
- Amgen Research (Munich) GmbH · 1 shared drug class
- Bayer · 1 shared drug class
- Beijing Anzhen Hospital · 1 shared drug class
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · 1 shared drug class
- Hospital General Universitario Gregorio Marañon · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Vincentage Pharma Co., Ltd:
- Vincentage Pharma Co., Ltd pipeline updates — RSS
- Vincentage Pharma Co., Ltd pipeline updates — Atom
- Vincentage Pharma Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Vincentage Pharma Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vincentage-pharma-co-ltd. Accessed 2026-06-09.